Rock Springs Capital Management LP Maintains Position in Puma Biotechnology (PBYI); Amazon Com (AMZN) Holder Picton Mahoney Asset Management Has Lifted Position by $2.30 Million as Valuation Declined

Amazon.com, Inc. (NASDAQ:AMZN) Logo

Rock Springs Capital Management Lp increased its stake in Puma Biotechnology Inc (PBYI) by 2.48% based on its latest 2018Q3 regulatory filing with the SEC. Rock Springs Capital Management Lp bought 11,800 shares as the company’s stock declined 49.57% with the market. The hedge fund held 487,600 shares of the major pharmaceuticals company at the end of 2018Q3, valued at $22.36M, up from 475,800 at the end of the previous reported quarter. Rock Springs Capital Management Lp who had been investing in Puma Biotechnology Inc for a number of months, seems to be bullish on the $1.03 billion market cap company. The stock increased 2.55% or $0.67 during the last trading session, reaching $26.99. About 396,294 shares traded. Puma Biotechnology, Inc. (NYSE:PBYI) has declined 77.02% since February 11, 2018 and is downtrending. It has underperformed by 77.02% the S&P500. Some Historical PBYI News: 08/03/2018 – PUMA BIOTECHNOLOGY SAYS GIVEN WRITTEN NOTICE TO EMA TO REQUEST RE-EXAMINATION OF NEGATIVE OPINION ISSUED BY CHMP IN FEB 2018 FOR MAA FOR NERATINIB; 12/04/2018 – Puma Lifts Earnings Forecast on Strong Sales and Profitability; 10/04/2018 – NOVARTIS’S AFINITOR GETS FDA OK FOR TSC PARTIAL-ONSET SEIZURES; 07/03/2018 – Panther Orthopedics, Inc. Receives FDA 510(k) Clearance for the PUMA System(TM) – An Orthopedic Flexible Fixation Device; 09/04/2018 – PUMA SE PUMG.DE : HSBC RAISES TARGET PRICE TO EUR 500 FRM EUR 425; 12/04/2018 – PUMA SE PUMG.DE – NOW SEES 2018 CURRENCY-ADJUSTED SALES GROWTH BETWEEN 10% AND 12% (PREVIOUSLY EXPECTED OF AROUND 10%); 15/03/2018 – ClinicalTrial US: PUMA (Paediatric osseoUs Marrow Assessment) (PUMA); 12/04/2018 – PUMA SE PUMG.DE SEES FY 2018 OPERATING RESULT (EBIT) IN THE RANGE OF € 310 MILLION TO € 330 MILLION; 02/04/2018 – NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases; 03/04/2018 – Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America

Picton Mahoney Asset Management increased its stake in Amazon Com Inc (AMZN) by 4.22% based on its latest 2018Q3 regulatory filing with the SEC. Picton Mahoney Asset Management bought 1,149 shares as the company’s stock declined 15.37% with the market. The institutional investor held 28,379 shares of the consumer services company at the end of 2018Q3, valued at $56.84M, up from 27,230 at the end of the previous reported quarter. Picton Mahoney Asset Management who had been investing in Amazon Com Inc for a number of months, seems to be bullish on the $783.49 billion market cap company. The stock increased 0.43% or $6.82 during the last trading session, reaching $1595.04. About 2.13M shares traded. Amazon.com, Inc. (NASDAQ:AMZN) has risen 41.49% since February 11, 2018 and is uptrending. It has outperformed by 41.49% the S&P500. Some Historical AMZN News: 29/03/2018 – Trump escalates attack on Amazon, focusing on tax, shipping; 05/04/2018 – Amazon Prime Video Greenlights Lorena, a Docuseries from Jordan Peele’s Monkeypaw; 06/04/2018 – Greycroft’s Patricof says Amazon could be helping to destroy ‘the fabric of America’; 16/05/2018 – Whoever takes the job will be working under the weight of Jeff Bezos, Warren Buffett and Jamie Dimon; 17/05/2018 – Amazon Favored by 39 Hedge Funds, 13Fs Show; 16/04/2018 – Amazon shelves plans to sell, distribute drugs to hospitals- CNBC; 04/04/2018 – AMAZON REPORTS NEW FULFILLMENT CENTER IN SOUTHERN NEVADA; 10/05/2018 – AMAZON.COM INC – RYANAIR PLANS TO CLOSE THE VAST MAJORITY OF ITS DATACENTERS OVER THE NEXT THREE YEARS; 27/03/2018 – Tech companies, like Amazon, Apple and IBM, all cover the surgery; 02/04/2018 – To Trump, It’s the `Amazon Washington Post.’ To Its Editor, That’s Baloney

Since December 3, 2018, it had 0 insider buys, and 8 insider sales for $506,784 activity. Shares for $25,011 were sold by EYLER CHARLES R on Thursday, January 3. BRYCE RICHARD PAUL also sold $25,011 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) on Thursday, January 3. Shares for $52,664 were sold by Lo Steven.

More notable recent Puma Biotechnology, Inc. (NASDAQ:PBYI) news were published by: Nasdaq.com which released: “Puma’s (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval – Nasdaq” on July 18, 2017, also Zacks.com with their article: “Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates – Zacks.com” published on August 09, 2018, Nasdaq.com published: “Interesting PBYI Put And Call Options For March 8th – Nasdaq” on January 24, 2019. More interesting news about Puma Biotechnology, Inc. (NASDAQ:PBYI) were released by: Nasdaq.com and their article: “Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect? – Nasdaq” published on May 07, 2018 as well as Seekingalpha.com‘s news article titled: “JPMorgan and Barclays bearish on Puma in premarket healthcare analyst action – Seeking Alpha” with publication date: November 02, 2018.

Rock Springs Capital Management Lp, which manages about $319.00 million and $2.76B US Long portfolio, decreased its stake in Gw Pharmaceuticals Plc (NASDAQ:GWPH) by 40,000 shares to 400,000 shares, valued at $69.10 million in 2018Q3, according to the filing. It also reduced its holding in Biogen Inc (NASDAQ:BIIB) by 3,000 shares in the quarter, leaving it with 50,000 shares, and cut its stake in Theravance Biopharma Inc (NASDAQ:TBPH).

Among 14 analysts covering Puma Biotechnology Inc (NYSE:PBYI), 7 have Buy rating, 2 Sell and 5 Hold. Therefore 50% are positive. Puma Biotechnology Inc had 74 analyst reports since August 27, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of PBYI in report on Thursday, May 25 with “Sector Perform” rating. The firm earned “Buy” rating on Monday, April 11 by UBS. The firm earned “Overweight” rating on Thursday, August 27 by JP Morgan. The rating was maintained by RBC Capital Markets on Wednesday, August 9 with “Hold”. J.P. Morgan maintained the stock with “Buy” rating in Tuesday, August 1 report. The firm has “Buy” rating given on Wednesday, January 24 by Bank of America. The stock of Puma Biotechnology, Inc. (NASDAQ:PBYI) earned “Neutral” rating by Goldman Sachs on Monday, November 19. The firm has “Buy” rating by Stifel Nicolaus given on Friday, May 11. The stock has “Outperform” rating by Leerink Swann on Monday, July 10. The firm has “Neutral” rating by Guggenheim given on Thursday, January 3.

Investors sentiment decreased to 0.99 in 2018 Q3. Its down 0.33, from 1.32 in 2018Q2. It is negative, as 29 investors sold PBYI shares while 39 reduced holdings. 19 funds opened positions while 48 raised stakes. 33.41 million shares or 10.98% less from 37.53 million shares in 2018Q2 were reported. Cubist Systematic Strategies Limited Liability Corp owns 0.02% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 8,035 shares. Morgan Stanley reported 0% stake. Virginia Retirement System Et Al invested in 0.01% or 22,600 shares. Vanguard Gru holds 0.01% or 2.82M shares. Jefferies Group Inc Limited Liability Co holds 0% or 2,200 shares in its portfolio. Royal Financial Bank Of Canada accumulated 5,387 shares or 0% of the stock. Federated Pa has 0.01% invested in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 89,800 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Puma Biotechnology, Inc. (NASDAQ:PBYI). California Pub Employees Retirement Sys reported 0% stake. Pictet Asset Management, a United Kingdom-based fund reported 419,486 shares. Aqr Capital Limited Liability Corp has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Emerald Advisers Inc Pa accumulated 244,008 shares or 0.41% of the stock. Parametric Portfolio Associates Ltd Limited Liability Company reported 0% stake. Verition Fund Management Limited Company stated it has 11,489 shares or 0.02% of all its holdings. Blackrock, New York-based fund reported 2.62 million shares.

Since August 15, 2018, it had 0 insider buys, and 16 selling transactions for $75.62 million activity. Shares for $5.31 million were sold by BEZOS JEFFREY P. $3.21M worth of stock was sold by Olsavsky Brian T on Thursday, November 15. Shares for $824,513 were sold by Reynolds Shelley. 1,726 Amazon.com, Inc. (NASDAQ:AMZN) shares with value of $3.28M were sold by Jassy Andrew R. 181 Amazon.com, Inc. (NASDAQ:AMZN) shares with value of $285,960 were sold by Huttenlocher Daniel P. Blackburn Jeffrey M sold 4,108 shares worth $8.02 million.

Among 57 analysts covering Amazon.com (NASDAQ:AMZN), 54 have Buy rating, 0 Sell and 3 Hold. Therefore 95% are positive. Amazon.com had 334 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Sunday, October 22 by Stifel Nicolaus. SunTrust maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, February 2. SunTrust has “Buy” rating and $1600.0 target. Deutsche Bank maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, April 27. Deutsche Bank has “Buy” rating and $180000 target. The rating was maintained by Nomura with “Buy” on Thursday, January 18. On Monday, January 18 the stock rating was initiated by Susquehanna with “Positive”. The stock of Amazon.com, Inc. (NASDAQ:AMZN) earned “Outperform” rating by Raymond James on Friday, October 27. The firm has “Hold” rating by Canaccord Genuity given on Friday, October 23. The rating was downgraded by Monness Crespi & Hardt on Monday, January 4 to “Neutral”. On Friday, April 29 the stock rating was maintained by Mizuho with “Buy”. The firm has “Buy” rating by Axiom Capital given on Tuesday, November 1.

Picton Mahoney Asset Management, which manages about $1.42 billion US Long portfolio, decreased its stake in Home Depot Inc (NYSE:HD) by 58,800 shares to 72,300 shares, valued at $14.98 million in 2018Q3, according to the filing. It also reduced its holding in Norfolk Southern Corp (NYSE:NSC) by 3,000 shares in the quarter, leaving it with 118,200 shares, and cut its stake in Matador Res Co (NYSE:MTDR).

Puma Biotechnology, Inc. (NASDAQ:PBYI) Institutional Positions Chart